PPARγ as a new therapeutic target in inflammatory bowel diseases
Open accessAbstract
The peroxisome proliferator activated receptor gamma(PPARgamma) is a nuclear receptor highly expressed in the colon and playing a key role in bacterial induced inflammation. Regulation of colon inflammation by this receptor has been well demonstrated in many experimental models of colitis but also in patients with ulcerative colitis, characterised by impaired expression of PPARgamma confined to their colon epithelial cells. Recent data showing that PPARgamma was the major functional receptor mediating the common aminosalicylate activities in inflammatory bowel diseases (IBD) have also reinforced the roles of this receptor in the control of intestinal inflammation. The aims of this review are to discuss the potential roles of PPARgamma in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chronic inflammatory disease conditions often reveal impaired PPARγ abundance.
“Interestingly, these disease conditions often revealed impaired PPAR␥ abundance (16,17).”
From MicroRNA-27b Contributes to Lipopolysaccharide-mediated Peroxisome Proliferator-activated Receptor γ (PPARγ) mRNA Destabilization (2010) · cites this paper as [17]
The Introduction reports 60% lower colonic PPARγ expression in patients with ulcerative colitis and impaired expression in a mouse model of ileitis. It also says expression in Crohn’s disease patients was comparable to controls, so it does not establish that chronic inflammatory disease conditions generally or often show reduced PPARγ abundance. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
This paper’s reference list could not be split into single entries.
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Review article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721 · see citing works
Kaser, A., Zeissig, S., & Blumberg, R. S. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101225 · Cited by 1,806 · see citing works
Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717 · see citing works
The role of gut microbiota in immune homeostasis and autoimmunity
Wu, H.-J., & Wu, E. (2012) · Gut Microbes · doi:10.4161/gmic.19320 · Cited by 1,426 · see citing works
Ruiz-Núñez, B., Pruimboom, L., Dijck-Brouwer, D. A. J., & Muskiet, F. A. J. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.02.009 · Cited by 246 · see citing works
Benedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2331460 · Cited by 242 · see citing works
Jennewein, C., von Knethen, A., Schmid, T., & Brüne, B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066399 · Cited by 183 · see citing works
Stress modulates intestinal secretory immunoglobulin a
Campos-Rodríguez, R., Godínez-Victoria, M., Abarca-Rojano, E., Pacheco-Yépez, J., Reyna-Garfias, H., Barbosa-Cabrera, R. E., & Drago-Serrano, M. E. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00086 · Cited by 119 · see citing works
Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease
Borniquel, S., Jansson, E. Å., Cole, M. P., Freeman, B. A., & Lundberg, J. O. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.014 · Cited by 92 · see citing works
Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study
Alhusayen, R. O., Juurlink, D. N., Mamdani, M. M., Morrow, R. L., Shear, N. H., & Dormuth, C. R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.387 · Cited by 84 · see citing works
Gut-microbiota derived bioactive metabolites and their functions in host physiology
Debnath, N., Kumar, R., Kumar, A., Mehta, P. K., & Yadav, A. K. (2021) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2021.1989847 · Cited by 77 · see citing works
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62 · see citing works
- Authors
- Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P., Chamaillard, M., & Desreumaux, P.
- Affiliations
- Inserm (FR)
- Corresponding author
- Desreumaux, P
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-08-11
- Volume
- 55
- Issue
- 9
- Pages
- 1341-1349
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC1860011
- OpenAlex
- W2136054045
- Cited by
- 450
- References
- 1
- Citations by year
- 2026: 18 · 2025: 14 · 2024: 36 · 2023: 34 · 2022: 21 · 2021: 20 · 2020: 18 · 2019: 17 · 2018: 22 · 2017: 13 · 2016: 13 · 2015: 21 · 2014: 16 · 2013: 24 · 2012: 39
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gut (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- PPARγ, inflammatory bowel disease, ulcerative colitis, colitis, intestinal inflammation, aminosalicylates, colonic epithelial cells, nuclear receptors, therapeutic target
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Colon, Humans, Ligands, Inflammatory Bowel Diseases, Mesalamine, PPAR gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
